Ipsen S.A. (OTCMKTS:IPSEY) Sees Significant Decrease in Short Interest

Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) was the target of a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 600 shares, a drop of 45.5% from the May 15th total of 1,100 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 1,300 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Ipsen in a research report on Wednesday, April 2nd.

Ipsen Stock Up 0.6%

Ipsen stock traded up $0.19 during trading on Monday, hitting $29.84. The company had a trading volume of 465 shares, compared to its average volume of 4,699. The company's 50 day simple moving average is $28.64 and its 200-day simple moving average is $29.24. Ipsen has a 1-year low of $25.11 and a 1-year high of $32.99.

Ipsen Increases Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th will be issued a $0.2896 dividend. This represents a dividend yield of 0.97%. This is a boost from Ipsen's previous dividend of $0.23. The ex-dividend date of this dividend is Monday, June 9th.

About Ipsen

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.